Cure8 research brief
A breath-based VOC test could offer a noninvasive, point-of-care way to help detect or screen for colon diseases including IBD. This study shows preliminary promise—especially for ulcerative colitis—but is early-stage and not yet ready for clinical use.
Clinicians, researchers, and patients interested in noninvasive diagnostics, biomarkers, and IBD/colorectal disease detection.
This paper reports an exploratory clinical study testing a bedside differential ion mobility spectrometry (DMS) device plus machine learning to read volatile organic compounds (VOCs) in exhaled breath and distinguish people with colon diseases from healthy controls.
The study enrolled 50 participants including patients with inflammatory bowel disease (IBD), diverticulosis, and healthy controls.
Machine-learning models showed moderate ability to separate colon-disease cases from controls overall (best ROC‑AUC reported 0.784), with higher discrimination for ulcerative colitis (ROC‑AUC 0.862) and lower discrimination for Crohn’s disease versus diverticular disease.
The study is presented as a feasibility/diagnostic-performance investigation rather than a validation study. Results suggest the approach is promising but preliminary: the sample size is small, disease groups are heterogeneous, and the analysis used exploratory machine-learning models.
The paper notes permutation testing to assess chance findings but does not report clinical diagnostic thresholds or external validation.
If you’re considering this as a future diagnostic option, understand it’s an early-stage research result showing potential that would require larger, multicenter validation and standardization of breath collection, device calibration, and model testing before clinical use.
Study is exploratory with small sample size and heterogeneous disease groups; results need external validation and standardization before clinical application.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.
